Silver Book Fact
Macugen to treat wet age-related macular degeneration (AMD)
A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.
Gragoudas E, Adamis A, Cunningham E, Feinsod M, et al. Pegaptanib for Neovascular Age-Related Macular Degeneration. NEJM. 2004; 351(27): 2805-16. http://content.nejm.org/cgi/content/abstract/351/27/2805